Hanhart J, et al. - Experts evaluated the mortality related to intravitreal injections of bevacizumab for age-related macular degeneration (AMD) in patients previously diagnosed with stroke or transient ischaemic attack (TIA). They performed Survival analysis using adjusted Cox regression. Findings suggested that compared to patients for whom there was no record of a prescription to any anti-VEGF agent, patients treated with bevacizumab for AMD demonstrated increased mortality within three months after a cerebrovascular event.